Designing biorelevant dissolution tests for lipid formulations: Case example – Lipid suspension of RZ-50

2008 ◽  
Vol 69 (2) ◽  
pp. 776-785 ◽  
Author(s):  
Ekarat Jantratid ◽  
Niels Janssen ◽  
Hitesh Chokshi ◽  
Kin Tang ◽  
Jennifer B. Dressman
2019 ◽  
Vol 108 (11) ◽  
pp. 3461-3477 ◽  
Author(s):  
Domagoj Segregur ◽  
Talia Flanagan ◽  
James Mann ◽  
Andrea Moir ◽  
Eva M. Karlsson ◽  
...  

2016 ◽  
Vol 105 ◽  
pp. 193-202 ◽  
Author(s):  
Cord J. Andreas ◽  
Irena Tomaszewska ◽  
Uwe Muenster ◽  
Dorina van der Mey ◽  
Wolfgang Mueck ◽  
...  

ADMET & DMPK ◽  
2017 ◽  
Vol 5 (1) ◽  
pp. 39 ◽  
Author(s):  
Lucie Gruberová ◽  
Bohumil Kratochvil

<p class="ADMETabstracttext">The choice of an appropriate medium for dissolution tests is an essential step during a dosage form development. The adequate design of dissolution testing enables forecasting in vivo behavior of drug formulation. Biorelevant media were developed for this purpose because dissolution media described in the International Pharmacopoeia are not thoroughly suitable. Therefore, we carried out solubility and dissolution tests in biorelevant media and we compared the results with data measured in compendial dissolution media. A shake-flask method and standard paddle apparatus were used. The concentration was measured by a UV-Vis spectrophotometer. An oral solid dosage form with poorly soluble drug candesartan cilexetil was tested. Significant differences in the solubility and dissolution profiles of candesartan cilexetil were observed. The study offers the overview of compendial and biorelevant media simulating fasted state that can be analyzed by a spectrophotometric technique.</p>


2000 ◽  
Vol 7 (1) ◽  
pp. 8-11 ◽  
Author(s):  
Eleftheria Nicolaides ◽  
John M. Hempenstall ◽  
Christos Reppas

2009 ◽  
Vol 37 (3-4) ◽  
pp. 434-441 ◽  
Author(s):  
Ekarat Jantratid ◽  
Vincenzo De Maio ◽  
Emanuela Ronda ◽  
Valentina Mattavelli ◽  
Maria Vertzoni ◽  
...  

2019 ◽  
Vol 25 (14) ◽  
pp. 1616-1622 ◽  
Author(s):  
Gabriela Muniz Félix Araújo ◽  
Gabriela Muniz Félix Araújo ◽  
Alana Rafaela Albuquerque Barros ◽  
Alana Rafaela Albuquerque Barros ◽  
João Augusto Oshiro-Junior ◽  
...  

Leishmaniasis is one of the most neglected diseases in the world. Its most severe clinical form, called visceral, if left untreated, can be fatal. Conventional therapy is based on the use of pentavalent antimonials and includes amphotericin B (AmB) as a second-choice drug. The micellar formulation of AmB, although effective, is associated with acute and chronic toxicity. Commercially-available lipid formulations emerged to overcome such drawbacks, but their high cost limits their widespread use. Drug delivery systems such as nanoemulsions (NE) have proven ability to solubilize hydrophobic compounds, improve absorption and bioavailability, increase efficacy and reduce toxicity of encapsulated drugs. NE become even more attractive because they are inexpensive and easy to prepare. The aim of this work was to incorporate AmB in NE prepared by sonicating a mixture of surfactants, Kolliphor® HS15 (KHS15) and Brij® 52, and an oil, isopropyl myristate. NE exhibited neutral pH, conductivity values consistent with oil in water systems, spherical structures with negative Zeta potential value, monomodal size distribution and average diameter of drug-containing droplets ranging from 33 to 132 nm. AmB did not modify the thermal behavior of the system, likely due to its dispersion in the internal phase. Statistically similar antileishmanial activity of AmB-loaded NE to that of AmB micellar formulation suggests further exploring them in terms of toxicity and effectiveness against amastigotes, with the aim of offering an alternative to treat visceral leishmaniasis.


2018 ◽  
Vol 15 (12) ◽  
pp. 5741-5753 ◽  
Author(s):  
Zahari Vinarov ◽  
Vladimir Katev ◽  
Nikola Burdzhiev ◽  
Slavka Tcholakova ◽  
Nikolai Denkov

Sign in / Sign up

Export Citation Format

Share Document